The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Botanical Medicines for the Treatment of Cancer: Rationale, Overview of Current Data, and Methodological Considerations for Phase I and II Trials
Abstract
There appears to be exceptional and growing public enthusiasm for botanical, or "herbal", medicines, especially amongst cancer patients. This has recently begun to be matched by increasing scientific attention. Whilst it is known that plant extracts are active against cancer, the standard approach has been to isolate, synthesize and administer the single chemical compound thought responsible for this effect. However, different components in a botanical may have synergistic activities. There is also some evidence that the presence of multiple compounds in a botanical extract can buffer the toxic effects of a single constituent. Though many of the botanicals popular among patients are probably not of benefit (e.g. Mistletoe, Pau D'arco), several botanicals have shown promise in Phase III (Sho-saiko-to, PSK) or Phase II (PC-SPES) trial. Quality control of botanicals poses significant challenges: small differences in genetics, soil, temperature, moisture and time of harvesting can lead to significant differences in the concentration of important constituents. Phase I and II methodology is also problematic: botanicals have low toxicity and are unlikely to cause rapid tumor regression. There is currently minimal regulation of botanical medicines.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Marotti, M., Piccaglia, R., Giovanelli, E., Deans, S. G., & Eaglesham, E. (1994) · Journal of Essential Oil Research · doi:10.1080/10412905.1994.9698325 · Cited by 83
Cited by
Antiinflammatory and Immunomodulating Properties of FungalMetabolites
Lull, C., Wichers, H. J., & Savelkoul, H. F. J. (2005) · Mediators of Inflammation · doi:10.1155/mi.2005.63 · Cited by 346
Gavamukulya, Y., Abou-Elella, F., Wamunyokoli, F., & AEl-Shemy, H. (2014) · Asian Pacific Journal of Tropical Medicine · doi:10.1016/s1995-7645(14)60258-3 · Cited by 264
Current Perspectives in the Application of Medicinal Plants Against Cancer: Novel Therapeutic Agents
Gezici, S., & Şekeroğlu, N. (2019) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520619666181224121004 · Cited by 258
Blechnum Orientale Linn - a fern with potential as antioxidant, anticancer and antibacterial agent
Lai, H. Y., Lim, Y. Y., & Kim, K. H. (2010) · BMC Complementary and Alternative Medicine · doi:10.1186/1472-6882-10-15 · Cited by 121
“It has been estimated that approximately two-thirds of anticancer drugs approved worldwide up to 1994 were derived from plant sources [3].”
BackgroundCytotoxic, apoptotic and antioxidant activity of the essential oil of Amomum tsao-ko
Yang, Y., Yue, Y., Runwei, Y., & Guolin, Z. (2010) · Bioresource Technology · doi:10.1016/j.biortech.2009.12.131 · Cited by 120
Metadata
- Authors
- Vickers, A.
- Venue
- Cancer Investigation
- Publisher
- Informa UK Limited
- Published
- 2002-01
- Volume
- 20
- Issue
- 7-8
- Pages
- 1069-1079
- ISSN
- 0735-7907 (ISSN-L)
- 1532-4192
- OpenAlex
- W2141393875
- Cited by
- 168
- References
- 1
- FWCI
- 10.95
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Botanical Medicines for the Treatment of Cancer: Rationale, Overview of Current Data, and Methodological Considerations for Phase I and II Trials. https://app.cochat.ai/papers/10.1081/cnv-120005926
- The paper
- Vickers, A. (2002). Botanical Medicines for the Treatment of Cancer: Rationale, Overview of Current Data, and Methodological Considerations for Phase I and II Trials. Cancer Investigation. https://doi.org/10.1081/cnv-120005926
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.